Department for Coagulation Disorders, University of Lund, University Hospital, Malmö, Sweden.
Haemophilia. 1999 May;5 Suppl 2:60-3. doi: 10.1046/j.1365-2516.1999.0050s2060.x.
There are several plasma derived von Willebrand factors (vWF) containing factor (FVIII) concentrates that can be used in the treatment of von Willebrand disease (vWD). All concentrates are effective in attaining normal postinfusion levels or of FVIII:C but it is difficult to achieve normalization of the bleeding time even with concentrates containing almost all vWF multimers including those of high molecular weight. Haemate P (Centeon) may be considered as the golden standard concentrate available at present. However, the development of more purified vWF concentrates devoid of FVIII:C is the goal for future development.
有几种含有因子 VIII(FVIII)的血浆衍生的血管性血友病因子(vWF)浓缩物可用于治疗血管性血友病(vWD)。所有浓缩物都能有效地达到 FVIII:C 的正常输注后水平,但即使使用含有几乎所有 vWF 多聚体(包括高分子量多聚体)的浓缩物,也很难使出血时间正常化。Haemate P(Centeon)可被视为目前可用的金标准浓缩物。然而,开发不含 FVIII:C 的更纯化的 vWF 浓缩物是未来的发展目标。